Olympus acquires well-known machinery companies and deploys new business

Medical News, June 3, May 28-Olympus Corporation ("Olympus"-Director, Representative Executive Officer, President and Chief Executive Officer: Yasuo Takeuchi) today announced that it has completed the acquisition of Israeli medical equipment Acquisition of the company Medi-Tate Ltd.
("Medi-Tate"-CEO: Ido Kilemnik) After announcing the decision to exercise the call option in February 2021.

 

Through this acquisition, Olympus has expanded its business line to provide in-office treatments for benign prostatic hyperplasia (BPH) and consolidate its leading position in the field of urological devices.

 

Nacho Abia, Chief Operating Officer of Olympus, said: "The acquisition of MediTate is in line with our corporate strategy to focus on three priority treatment areas .
Our treatment solutions division-gastrointestinal treatment equipment, urology equipment and endorespiratory treatment equipment.
Medi-Tate’s innovative products provide true healthcare professionals with minimally invasive treatment options and the flexibility to provide care for patients.
"

 

The acquisition has long been planned

 

Medi-Tate is an Israeli medical device company.
Mainly through effective non-surgical solutions for benign prostatic hyperplasia (BPH) to improve men's medical care and quality of life.
The flagship iTind treatment for BPH currently has the European Union CE mark and has been approved for use in the European Union, the United Kingdom, Israel, Australia, Brazil and the FDA in the United States.

 

Olympus made an initial investment in Medi-Tate in November 2018.
The agreement includes the right to distribute Medi-Tate products and gives Olympus the option to acquire 100% of the Israeli company in the future.

 

Medi-Tate CEO Ido Kilemnik commented: “We believe Olympus appreciates our attention to the long-term clinical results and the dedication of the entire Medi-Tate team.
We are very happy to join Olympus, it shares with us The vision of iTind is to make iTind the global standard for BPH treatment ; I am very happy to cooperate with Olympus and work together to improve the quality of life of patients.
"

 

A new alternative to BPH treatment-iTind treatment

 

The minimally invasive treatment supported by iTind is iTind, a temporarily implanted nitinol device that supports the relief of symptoms caused by lower urinary tract BPH (LUTS).
iTind treatment is a simple procedure performed by a urologist in a hospital or clinic.
The device is placed in the prostatic urethra in a folded configuration.
The symptoms of most patients are relieved quickly and sexual function is preserved.
The operation is simple and can be completed in the outpatient clinic without the need for a catheter.
During the course of 5 to 7 days of treatment, it slowly expands and applies gentle pressure at three precise points to enlarge the opening where urine flows through the prostatic urethra and then exits the body.
After 5 to 7 days, the device will be completely removed.
Clinical trials have shown that the newly remodeled prostatic urethra will continue to provide long-term relief of BPH symptoms.

 

BPH that old men will face

 

A healthy prostate is about the shape and size of a walnut.
As men age, the prostate usually gets larger.
This very common process is called benign prostatic hyperplasia (BPH), or enlarged prostate.
This can cause the prostate to press on the urethra, leading to chronic and sometimes troublesome symptoms of the lower urinary tract, which can seriously affect the quality of life.

 

　　Benign prostatic hyperplasia (BPH) is one of the most common diseases in elderly men, and it is also the most common lower urinary tract symptom.
It is understood that about 80% of men with BPH will face it in their lifetime.
The prevalence rate for men aged 51 to 60 is about 50%, while the prevalence rate for men aged 81 to 90 is as high as 90%.
%, it can be seen that the prevalence of BPH increases with age.
This non-cancerous prostate growth disease affects more than 500 million men worldwide.
In addition, about 40% of men over the age of 50 in my country suffer from this disease.
With the aging of the Chinese population, the market demand for BPH treatment products will gradually increase.

 

　　Drugs and surgical treatment have always been one of the common treatment options for BPH.
In recent years, more and more minimally invasive surgical treatment devices have entered the market.
Through the acquisition of Medi-Tate and the combination of its product iTind, Olympus can provide urologists with more treatment options based on the patient’s symptoms and needs, ranging from daytime treatment in the office to surgical treatment in the hospital.
The clinical treatment of BPH covers all aspects of the treatment scene, marking Olympus as the market leader of BPH treatment equipment and increasing its market share in the field of BPH treatment.

　　Medical News, June 3, May 28-Olympus Corporation ("Olympus"-Director, Representative Executive Officer, President and Chief Executive Officer: Yasuo Takeuchi) today announced that it has completed the acquisition of Israeli medical equipment Acquisition of the company Medi-Tate Ltd.
("Medi-Tate"-CEO: Ido Kilemnik) After announcing the decision to exercise the call option in February 2021.

 

　　Through this acquisition, Olympus has expanded its business line to provide in-office treatments for benign prostatic hyperplasia (BPH) and consolidate its leading position in the field of urological devices.

 

　　Nacho Abia, Chief Operating Officer of Olympus, said: "The acquisition of MediTate is in line with our corporate strategy to focus on three priority treatment areas .
Our treatment solutions division-gastrointestinal treatment equipment, urology equipment and endorespiratory treatment equipment.
Medi-Tate’s innovative products provide true healthcare professionals with minimally invasive treatment options and the flexibility to provide care for patients.
"

 

　　The acquisition has long been planned

 

　　Medi-Tate is an Israeli medical device company.
Mainly through effective non-surgical solutions for benign prostatic hyperplasia (BPH) to improve men's medical care and quality of life.
The flagship iTind treatment for BPH currently has the European Union CE mark and has been approved for use in the European Union, the United Kingdom, Israel, Australia, Brazil and the FDA in the United States.

 

　　Olympus made an initial investment in Medi-Tate in November 2018.
The agreement includes the right to distribute Medi-Tate products and gives Olympus the option to acquire 100% of the Israeli company in the future.

 

　　Medi-Tate CEO Ido Kilemnik commented: “We believe Olympus appreciates our attention to the long-term clinical results and the dedication of the entire Medi-Tate team.
We are very happy to join Olympus, it shares with us The vision of iTind is to make iTind the global standard for BPH treatment ; I am very happy to cooperate with Olympus and work together to improve the quality of life of patients.
"

 

　　A new alternative to BPH treatment-iTind treatment

 

　　The minimally invasive treatment supported by iTind is iTind, a temporarily implanted nitinol device that supports the relief of symptoms caused by lower urinary tract BPH (LUTS).
iTind treatment is a simple procedure performed by a urologist in a hospital or clinic.
The device is placed in the prostatic urethra in a folded configuration.
The symptoms of most patients are relieved quickly and sexual function is preserved.
The operation is simple and can be completed in the outpatient clinic without the need for a catheter.
During the course of 5 to 7 days of treatment, it slowly expands and applies gentle pressure at three precise points to enlarge the opening where urine flows through the prostatic urethra and then exits the body.
After 5 to 7 days, the device will be completely removed.
Clinical trials have shown that the newly remodeled prostatic urethra will continue to provide long-term relief of BPH symptoms.

 

　　BPH that old men will face

 

　　A healthy prostate is about the shape and size of a walnut.
As men age, the prostate usually gets larger.
This very common process is called benign prostatic hyperplasia (BPH), or enlarged prostate.
This can cause the prostate to press on the urethra, leading to chronic and sometimes troublesome symptoms of the lower urinary tract, which can seriously affect the quality of life.

 

　　Benign prostatic hyperplasia (BPH) is one of the most common diseases in elderly men, and it is also the most common lower urinary tract symptom.
It is understood that about 80% of men with BPH will face it in their lifetime.
The prevalence rate for men aged 51 to 60 is about 50%, while the prevalence rate for men aged 81 to 90 is as high as 90%.
%, it can be seen that the prevalence of BPH increases with age.
This non-cancerous prostate growth disease affects more than 500 million men worldwide.
In addition, about 40% of men over the age of 50 in my country suffer from this disease.
With the aging of the Chinese population, the market demand for BPH treatment products will gradually increase.

 

　　Drugs and surgical treatment have always been one of the common treatment options for BPH.
In recent years, more and more minimally invasive surgical treatment devices have entered the market.
Through the acquisition of Medi-Tate and the combination of its product iTind, Olympus can provide urologists with more treatment options based on the patient’s symptoms and needs, ranging from daytime treatment in the office to surgical treatment in the hospital.
The clinical treatment of BPH covers all aspects of the treatment scene, marking Olympus as the market leader of BPH treatment equipment and increasing its market share in the field of BPH treatment.